Viridian Therapeutics, Inc. $VRDN Stake Cut by JPMorgan Chase & Co.

JPMorgan Chase & Co. lessened its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 25.7% during the 3rd quarter, HoldingsChannel reports. The fund owned 309,133 shares of the company’s stock after selling 106,856 shares during the period. JPMorgan Chase & Co.’s holdings in Viridian Therapeutics were worth $6,671,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. US Bancorp DE increased its position in Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Viridian Therapeutics by 1.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after buying an additional 876 shares in the last quarter. Sei Investments Co. grew its stake in shares of Viridian Therapeutics by 10.0% in the 3rd quarter. Sei Investments Co. now owns 11,556 shares of the company’s stock valued at $249,000 after buying an additional 1,046 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its holdings in Viridian Therapeutics by 2.4% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 59,410 shares of the company’s stock worth $1,282,000 after buying an additional 1,386 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Viridian Therapeutics by 1.3% during the 2nd quarter. Swiss National Bank now owns 108,900 shares of the company’s stock worth $1,522,000 after purchasing an additional 1,400 shares during the last quarter.

Viridian Therapeutics Stock Up 5.6%

Viridian Therapeutics stock opened at $19.56 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. Viridian Therapeutics, Inc. has a fifty-two week low of $9.90 and a fifty-two week high of $34.29. The firm has a fifty day moving average price of $29.16 and a two-hundred day moving average price of $27.89. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -5.95 and a beta of 1.00.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%. As a group, analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: REVEAL‑1 hit its primary endpoint: elegrobart produced statistically significant proptosis responder rates (Q4W 54%, Q8W 63% vs placebo 18%) — an important clinical validation that supports a potential approval path. Business Wire release
• Positive Sentiment: Multiple outlets reported the positive topline data (press coverage that confirms the readout and its details may help downstream regulatory and partnering discussions). Las Vegas Sun article
• Positive Sentiment: Some sell‑side firms remain constructive despite cuts — Goldman Sachs cut its target to $36 but kept a “buy” rating, Wedbush cut to $37 and kept “outperform”, and Needham trimmed to $32 while retaining “buy” — these keep a material upside narrative for investors who focus on longer‑term commercial potential. Benzinga
• Neutral Sentiment: Market commentary and audio/newscasts are covering the swing (podcast coverage and “stocks to watch” lists) — reflects heightened attention but does not add new clinical or financial data. Bloomberg podcast
• Neutral Sentiment: News aggregators and analysts explain the paradox: the trial met its primary endpoint but market expectations for effect size, secondary endpoints, safety, dosing, or commercial assumptions may not have been met — this discussion is driving intraday volatility. Seeking Alpha
• Negative Sentiment: Several analysts trimmed price targets and/or lowered ratings: Wells Fargo cut target to $20 and moved to “equal weight”, HC Wainwright cut to $22 (still “buy”) — these downward revisions compress near‑term upside and signal more conservative commercial or launch assumptions. Benzinga
• Negative Sentiment: Despite positive topline data, the stock plunged (>30% in earlier trading) on investor disappointment and profit‑taking; coverage highlighting the selloff and “stock tumbles despite trial success” may amplify short‑term selling pressure. Investing.com

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on VRDN shares. Royal Bank Of Canada decreased their price objective on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Needham & Company LLC decreased their price target on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a research note on Monday. Wells Fargo & Company lowered their price objective on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a report on Tuesday. William Blair started coverage on Viridian Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Finally, Wall Street Zen lowered Viridian Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.21.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.